Global Retirement Partners LLC boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 16.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,365 shares of the medical device company’s stock after purchasing an additional 188 shares during the quarter. Global Retirement Partners LLC’s holdings in DexCom were worth $160,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. KB Financial Partners LLC bought a new position in shares of DexCom in the 1st quarter valued at about $72,000. James Investment Research Inc. purchased a new stake in DexCom during the fourth quarter valued at approximately $27,000. Whittier Trust Co. lifted its stake in shares of DexCom by 684.4% in the 1st quarter. Whittier Trust Co. now owns 251 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 219 shares during the last quarter. CoreCap Advisors LLC purchased a new position in shares of DexCom in the 4th quarter worth approximately $35,000. Finally, Core Alternative Capital increased its position in shares of DexCom by 103.2% during the 1st quarter. Core Alternative Capital now owns 382 shares of the medical device company’s stock valued at $44,000 after purchasing an additional 194 shares during the last quarter. Institutional investors own 93.97% of the company’s stock.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on DXCM. Stifel Nicolaus raised their price target on DexCom from $130.00 to $140.00 in a research report on Friday, April 28th. Canaccord Genuity Group lifted their price target on shares of DexCom from $135.00 to $150.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. UBS Group upped their price target on shares of DexCom from $142.00 to $150.00 in a report on Friday, April 28th. Morgan Stanley initiated coverage on shares of DexCom in a research note on Tuesday, May 30th. They issued an “equal weight” rating and a $131.00 price objective for the company. Finally, Raymond James upped their target price on DexCom from $140.00 to $154.00 in a research note on Friday, July 28th. Three research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $139.94.
DexCom Stock Up 2.1 %
DexCom stock opened at $113.27 on Friday. DexCom, Inc. has a fifty-two week low of $78.94 and a fifty-two week high of $139.55. The company has a market cap of $43.93 billion, a PE ratio of 131.71, a PEG ratio of 2.38 and a beta of 1.15. The company has a debt-to-equity ratio of 1.16, a quick ratio of 2.21 and a current ratio of 2.42. The business’s 50-day simple moving average is $126.98 and its two-hundred day simple moving average is $119.30.
DexCom (NASDAQ:DXCM – Get Free Report) last released its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.22 by $0.12. DexCom had a net margin of 11.18% and a return on equity of 22.01%. The business had revenue of $871.30 million for the quarter, compared to the consensus estimate of $841.16 million. During the same period in the prior year, the firm earned $0.17 EPS. The business’s revenue for the quarter was up 25.2% on a year-over-year basis. Equities analysts anticipate that DexCom, Inc. will post 1.19 EPS for the current year.
Insiders Place Their Bets
In other DexCom news, CFO Jereme M. Sylvain sold 2,400 shares of DexCom stock in a transaction dated Monday, May 22nd. The stock was sold at an average price of $117.58, for a total transaction of $282,192.00. Following the completion of the transaction, the chief financial officer now owns 74,711 shares in the company, valued at approximately $8,784,519.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Steven Robert Pacelli sold 412 shares of the firm’s stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $118.65, for a total transaction of $48,883.80. Following the sale, the director now owns 132,274 shares of the company’s stock, valued at approximately $15,694,310.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jereme M. Sylvain sold 2,400 shares of DexCom stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $117.58, for a total transaction of $282,192.00. Following the transaction, the chief financial officer now directly owns 74,711 shares of the company’s stock, valued at $8,784,519.38. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,567 shares of company stock valued at $1,493,790. Company insiders own 0.41% of the company’s stock.
DexCom Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
See Also
- Five stocks we like better than DexCom
- Trading Stocks: RSI and Why it’s Useful
- Alibaba Explodes On Earnings, Inching Toward Triple Digit Prices
- How to Invest in Communication Stocks
- Is It Time To Game The Roblox Market?
- How to Invest in Electric Cars
- 2 Cheap Stocks The Insiders Are Buying
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
